Quick Search:       Advanced Search
Chinese Version 
Online office
Journal Online
Download
Top
Links

扫描微信二维码,获取更多信息
Efficacy and Safety of Flos Abelmoschus Manihot (Malvaceae) on Type 2 Diabetic Nephropathy: A Systematic Review
  
View Full Text  View/Add Comment  Download reader
KeyWord:Flos Abelmoschus manihot, Huangkui Capsule, Chinese medicine, type 2 diabetic nephropathy, systematic review, meta-analysis, randomized controlled trial
Author NameAffiliationE-mail
CHEN Yi-zhi, GONG Zhi-xiang, CAI Guang-yan   
CHEN Xiang-mei Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing (100853), China xmchen301@126.com 
Hits: 1073
Download times: 179
Abstract:
      bjective: To evaluate the efficacy and safety of Flos Abelmoschus manihot (Malvaceae) on type 2 diabetic nephropathy (DN). Methods: The Cochrane Library, PubMed/MEDLINE, Excerpta Medical Database, Chinese electronic literature databases, and the references of relevant articles were searched in March 2012 for randomized controlled trials (RCTs) that reported the effects of Flos A. manihot on type 2 DN patients with overt but subnephrotic-range proteinuria (500–3,500 mg/24 h). The quality of trials was evaluated using the Cochrane-recommended method. The results were summarized as risk ratios (RRs) for dichotomous outcomes or mean differences (MDs) for continuous outcomes. Results: Seven trials (531 patients) were included. Flos A. manihot significantly decreased proteinuria [MD –317.32 mg/24 h, 95% confidence interval (CI) [–470.48, –164.17], P<0.01]. After excluding a trial that only included patients with well-preserved renal function, Flos A. manihot was associated with a significant decrease in serum creatinine (MD –11.99 μmol/L, 95% CI [–16.95, –7.04], P<0.01). Serious adverse events were not observed. The most common adverse event was mild to moderate gastrointestinal discomfort; however, patients receiving this herb did not have an increased risk for tolerated gastrointestinal discomfort (RR 1.48, 95% CI [0.39, 5.68], P=0.57). Conclusions: Flos A. manihot may be considered as an important adjunctive therapy with the first-line and indispensable therapeutic strategies for type 2 DN. High-quality RCTs are urgently needed to confirm the effect of Flos A. manihot on definite endpoints such as end-stage renal disease.
Close